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INTRODUCTION:  We  experienced  two  esophageal  cancer  patients  who  developed  severe  acute  renal
failure  after  neoadjuvant  chemotherapy  with  cisplatin  and  5-ﬂuorourasil.
PRESENTATION  OF  CASE:  After  administration  of cisplatin,  their  serum  creatinine  increased  gradually  until
they  required  hemodialysis  and their  renal  failure  was  permanent.  In  both  cases,  renal  biopsy  exami-
nation  indicated  partial  recovery  of the  proximal  tubule,  but renal  function  did  not recover.  After  these
events,  one  patient  underwent  deﬁnitive  radiotherapy  and  the  other  underwent  esophagectomy  for  their
esophageal  cancers,  while  continuing  dialysis.  Both  patients  are  alive  without  cancer  recurrence.sophageal cancer
eoadjuvant chemotherapy
DISCUSSION:  In these  two cases  of  cisplatin-induced  renal  failure,  renal  biopsy  examination  showed  only
slight  disorder  of proximal  tubules  and  tendency  to recover.
CONCLUSION:  Although  cisplatin-related  nephrotoxicity  is  a well-recognized  complication,  there  have
been  few  reports  of  renal  failure  requiring  hemodialysis  in cancer  patients.  In  this  report,  we  present
their  clinical  courses  and the  pathological  ﬁndings  of  cisplatin-related  renal  failure.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
he  CCaccess  article  under  t
. Introduction
Cisplatin and related platinum-based therapeutics are used
idely in the treatment of a variety of cancers. However, the clinical
se of cisplatin can be complicated by myelotoxicity, ototoxic-
ty, nausea and vomiting, and nephrotoxicity [1]. Nephrotoxicity
econdary to cisplatin administration is dose-dependent, and the
rug-induced renal failure reﬂects acute tubular necrosis, which is
sually reversible.
We  experienced two cases of esophageal cancer with therapy-elated acute renal failure that developed during neoadjuvant
hemotherapy. These patients required dialysis, and their renal fail-
re was permanent. There have been few reports of renal failure in
Abbreviations: 18F-FDG PET/CT, 18F-ﬂuorodeoxy glucose positron emission
omography-computed tomography; UICC, the Union for International Cancer
ontrol; CTC-AE, the Common Terminology Criteria for Adverse Events; ARB,
ngiotensin II receptor blocker.
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210-2612/© 2016 The Authors. Published by Elsevier Ltd. on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/). BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
cancer patients undergoing chemotherapy, though therapy-related
nephrotoxicity is a well-recognized complication of chemothera-
peutic agents, including cisplatin. In this report, we present two
cases with their clinical courses and renal biopsy ﬁndings.
2. Presentation of case
2.1. Case 1
A 66-year-old man  was referred to our hospital for treatment
of his thoracic esophageal cancer. An irregularly elevated lesion
(type 0-IIa) occupied the middle thoracic esophagus, and biopsy
specimens from the lesion showed well-differentiated squamous
cell carcinoma (Fig. 1a–d). Computed tomography revealed wall
thickening in the middle thoracic esophagus and swelling of a mid-
dle thoracic para-esophageal lymph node. 18F-ﬂuorodeoxy glucose
positron emission tomography-computed tomography (18F-FDG
PET/CT) revealed high uptake at the tumor and lymph node. We
diagnosed the cancer as clinical stage T1bN1M0, stage IIB according
to the Union for International Cancer Control (UICC) classiﬁcation,
7th edition.
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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aig. 1. (a) Endoscopic examination showed an irregularly elevated lesion occupying 
b)  Esophagography showed an irregular outline at the middle thoracic esophagus.
ET/CT  revealed high uptake at the lymph node.
The patient underwent neoadjuvant chemotherapy consisting
f 80 mg/m2 cisplatin on day 1 and 800 mg/m2 5-ﬂuorouracil
n days 1–5. On day 5, however, the patient’s serum creatinine
evel had increased to 7.83 mg/ml  (Fig. 3a). We  diagnosed grade 4
cute renal failure based on the Common Terminology Criteria for
dverse Events (CTC-AE ver. 3.0), after which chemotherapy was
topped, and the patient was administered hemodialysis without
elay. On day 36, we performed a renal biopsy, and the specimen
ontained 24 glomeruli, 3 of which were sclerotic. Light microscopy
howed no mesangial proliferation. There was diffuse moderate
nterstitial inﬁltration of lymphocytes with tubulitis, mild inter-
titial ﬁbrosis, and mild arteriolar sclerosis (Fig. 4a). Tubular casts
ithout macrophagic reactions were seen. Immunoﬂuorescence
icroscopy showed no immunoglobulin or complement deposits,
nd electron microscopy revealed myeloid body-like particles in
he proximal tubules. The patient’s renal function was  expected to
ecover, but after 2 months of hemodialysis it had not. We  therefore
ecided to resume treatment of his esophageal cancer while con-
inuing hemodailysis. At that time, the patient was  suffering from
ongestive heart failure and interstitial pneumonia, so we admin-
stered deﬁnitive radiotherapy (60 Gy). It is 48 months since the
adiotherapy, and the patient is currently alive without recurrence
f his esophageal cancer.
.2. Case 2A 64-year-old man  was referred to our hospital for treatment of
is thoracic esophageal cancer. Endoscopic examination showed
n elevated tumor (type 1) with an irregular mucosal lesion (typeximately three-fourths of the esophageal circumference 34–36 cm from the incisors.
 revealed swelling of a middle thoracic para-esophageal lymph node. (d) 18F-FDG
0-IIb) located 35 cm from the patient’s incisors (Fig. 2a–f). Biopsy
specimens of the lesion showed modiﬁed differentiated squamous
cell carcinoma. Computed tomography revealed wall thickening in
the lower thoracic esophagus and swelling of a lymph node along
the left gastric artery. 18F-FDG PET/CT showed high uptake at the
tumor and lymph node, and the patient was diagnosed as clinical
stage T1bN1M0, stage IIB.
This patient also underwent neoadjuvant chemotherapy con-
sisting of 80 mg/m2 cisplatin on day 1 and 800 mg/m2 5-ﬂuorouracil
on days 1–5. On day 3, however, his serum creatinine had increased
to 3.35 mg/ml  (Fig. 3a). We  diagnosed acute renal failure at CTC-
AE grade 3 and stopped chemotherapy. Then on day 6, we began
administering hemodialysis because the patient’s serum creati-
nine had increased to 8.35 mg/ml. On day 36, while continuing
hemodialysis, we performed an esophagectomy through a right-
thoracotomy and 2-ﬁeld lymph node dissection, followed by
reconstruction with the gastric tube through the ante-thoracic
route. It is 49 months since the operation was performed, and
the patient is currently alive with no recurrence of his esophageal
cancer. At the time of the esophagectomy, a renal biopsy was
also performed. Light microscopy showed global sclerosis in 3
of 48 glomeruli with mild ischemic alteration. There was diffuse
mild interstitial inﬁltration by lymphocytes, vacuolar degeneration
in the proximal tubules, mild interstitial ﬁbrosis, and moderate
arteriolar sclerosis (Fig. 4b). Tubular casts without macrophagic
reactions were seen diffusely. Immunoﬂuorescence microscopy
showed no immunoglobulin or complement deposits. Electron
microscopy revealed enlarged lysosomes and endoplasmic retic-
ulum, and myeloid body-like particles in the tubules. Pathological
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rig. 2. (a) Endoscopic examination showed an elevated tumor (type 1) with an ir
rregular outline at the lower thoracic esophagus. (c and e) CT revealed wall thicke
rtery.  (d and f) 18F-FDG PET/CT revealed high uptake at the tumor and lymph nod
mages showed only slight disorder of the proximal tubule, which
ppeared to have partially recovered, though the patient’s renal
unction has not yet recovered.
. Discussion
It is recognized that about one-third of patients who  undergo
hemotherapy that includes cisplatin will experience nephro-
oxicity [2]. However, hemodialysis is rarely required. In one
tudy, for example, among 56 patients who developed mod-
rate renal dysfunction (creatinine clearance <60 ml/min), none
equired hemodialysis, and only two (3.5%) experienced grade 3 or
 serum creatinine elevations while being treated with cisplatin-
ontaining chemotherapy [3]. In fact, we had administered the
ame chemotherapeutic regimen, consisting of high-dose cisplatin
nd 5-ﬂuorouracil, to more than 500 esophageal cancer patients
ince 2003, and none experienced severe renal failure requiring
ialysis. Furthermore, we could not have foreseen the occurrence of
enal failure in the two patients described here, as their renal func-
ions were within the normal range (creatinine clearances were
30 ml/min and 122 ml/min, respectively).
Although the exact mechanism of cisplatin-induced nephrotox-
city remains unclear, exposing proximal tubular cells to cisplatin
eportedly activates complex signaling pathways and a multifac-r mucosal lesion located 35 cm from the incisors. (b) Esophagography showed an
 the lower thoracic esophagus and swelling of a lymph node along the left gastric
torial process that leads to tubular cell injury and death. Cisplatin
has multiple intracellular effects, including altered gene regulation,
direct cytotoxicity mediated by reactive oxygen species, induc-
tion of apoptosis, and stimulation of inﬂammation and ﬁbrogenesis
[4,5]. In addition, the plasma level of unbound free platinum is an
important determinant of cisplatin’s antitumor effects and nephro-
toxicity. Approximately 98% of cisplatin binds to plasma protein,
and the unbound free platinum is rapidly eliminated, mainly via the
kidneys such that it becomes undetectable within 2 h after infusing
cisplatin [6]. It is therefore important for patients receiving cis-
platin to be well hydrated for 2 or 3 h after infusion. Indeed, volume
expansion remains the most effective strategy for prevention of
cisplatin nephrotoxicity [7–10], though the two  patients described
here received sufﬁcient drip infusion (3899 ml/day in both) and
produced good urine volumes (3220 ml/day, 4830 ml/day) (Fig. 3b).
Recent randomized trials showed that addition of magnesium was
effective for reducing cisplatin-induced renal toxicity [11,12], and
we now add magnesium to the hydration ﬂuid.
A common feature of our two  patients was  that they were both
taking a calcium channel blocker and an angiotensin II receptor
blocker (ARB). It is thought that under some circumstances ARBs
may  contribute to the occurrence of acute renal failure by reducing
renal blood ﬂow. After infusion of cisplatin, the blood pressure in
case 1’s patient fell from 130 mmHg  to 80 mmHg, which suggests
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Fig. 3. (a) In case 1, the serum creatinine level was  elevated to 7.83 mg/ml on day 5. On day 6, the serum creatinine level reached 8.26 mg/ml. In case 2, the serum creatinine
level  increased gradually, reaching 3.35 mg/dl on day 4, 5.31 mg/dl on day 5, and 8.35 mg/ml  on day 6. (b) Both patients exhibited good urine volumes on days 1–5.
Fig. 4. Light microscopic examination of a renal biopsy sample from case 1’s patient showed diffuse moderate interstitial inﬁltration of lymphocytes with tubulitis, mild inter-
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ftitial  ﬁbrosis, and mild arteriolar sclerosis (a). Light microscopic examination of the
acuolar degeneration in the proximal tubules, mild interstitial ﬁbrosis, and moder
he possibility that diminished renal blood ﬂow contributed to his
enal failure.
It is also noteworthy that renal toxicity was slightly more severe
n patients treated with a generic cisplatin formulation than in
hose treated with an innovator formulation, especially in male
atients [13]. In our hospital, a generic cisplatin formulation was
dopted 5 years ago, and 49 patients administered the generic cis-
latin formulation exhibited elevations in serum creatinine to more
han 2 mg/dl (the total treated population was about 2500). We  are
ow investigating the relationship between the generic cisplatin
ormulation and nephrotoxicity.sy from case 2’s patient showed diffuse mild interstitial inﬁltration of lymphocytes,
teriolar sclerosis (b). Periodic acid-Schiff staining (×400).
In these two cases of cisplatin-induced renal failure, renal biopsy
examination showed only slight disorder of proximal tubules and
tendency to recover.
4. Conclusion
It is deeply regrettable that our two cancer patients suffered
permanent renal failure caused by preoperative treatment with
cisplatin. In these two cases of cisplatin-induced renal failure,
renal biopsy examination showed only slight disorder of proximal
tubules and tendency to recover. To prevent occurrences of per-
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anent renal failure in cancer patients administered cisplatin, we
uggest it is highly important to maintain sufﬁcient hydration, with
requent measurement of urine volume, serum creatinine and strict
ontrol of the blood pressure.
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